MedTrace Logo

Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia

NCT00231101 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-10-17

No results posted yet for this study

Summary

A single-blind switching study in which forty subjects currently being treated with risperidone will be randomly assigned to either stay on risperidone or switched to quetiapine. Various behavioral and biological measures will be used to compare smoking behavior over time in these two groups.

Conditions

  • Smoking Behavior in Schizophrenia

Interventions

DRUG

Quetiapine

Sponsors & Collaborators

  • Arthur P. Noyes Research Foundation

    lead OTHER

Principal Investigators

  • Richard C Josiassen, Ph.D. · Arthur P. Noyes Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231101 on ClinicalTrials.gov